Ana Isabel Ferreira

ORCID: 0000-0003-0076-840X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Inflammatory Bowel Disease
  • Colorectal Cancer Screening and Detection
  • Gastric Cancer Management and Outcomes
  • Gastrointestinal Bleeding Diagnosis and Treatment
  • Diverticular Disease and Complications
  • Helicobacter pylori-related gastroenterology studies
  • Microscopic Colitis
  • Gastrointestinal disorders and treatments
  • Autoimmune and Inflammatory Disorders
  • Esophageal and GI Pathology
  • Immunodeficiency and Autoimmune Disorders
  • Eosinophilic Esophagitis
  • Occupational Health and Burnout
  • Metastasis and carcinoma case studies
  • Colorectal Cancer Surgical Treatments
  • Gastrointestinal Tumor Research and Treatment
  • Business and Management Studies
  • Liver Disease Diagnosis and Treatment
  • Education and Work Dynamics
  • Intestinal and Peritoneal Adhesions
  • Omental and Epiploic Conditions
  • Drug-Induced Hepatotoxicity and Protection
  • Diagnosis and Treatment of Venous Diseases
  • Mycobacterium research and diagnosis
  • Endoplasmic Reticulum Stress and Disease

Hospital da Senhora da Oliveira Guimarães
2022-2025

University of Minho
2023-2025

Administração Regional de Saúde de Lisboa e Vale do Tejo
2024

Polytechnic Institute of Porto
2019

Universidad de Valladolid
2009

We aimed to develop and validate a simple capsule endoscopy (CE) training assessment tool, the Capsule Endoscopy Training Assessment (CETA), prospectively use it analyze learning progression achieved by participants in our CE program.

10.1111/jgh.16823 article EN Journal of Gastroenterology and Hepatology 2024-11-25

Recently, a formula of subcutaneous infliximab (SC-IFX) has been approved for inflammatory bowel disease (IBD), demonstrating better pharmacokinetic and immunogenic profiles, compared to intravenous (IV-IFX), with similar efficacy safety.

10.1097/meg.0000000000002835 article EN European Journal of Gastroenterology & Hepatology 2024-08-19

BACKGROUND Alpha-1 antitrypsin deficiency (AATD) is a codominant autosomal hereditary condition that predisposes patients to the development of lung and/or liver disease, and Pi*Z allele most clinically relevant mutation. AIM To evaluate impact clinical parameters AATD phenotypes, particularly allele, in fibrosis. METHODS Cross-sectional cohort study including consecutive with followed Pulmonology or Hepatology consultation. RESULTS Included 69 patients, 49.3% had Pi*MZ phenotype 10.1%...

10.4254/wjh.v16.i8.1099 article EN World Journal of Hepatology 2024-08-22

Introduction: Celiac disease has been associated with gastrointestinal malignancies, most commonly lymphoma. Nevertheless, rarer malignancies have also reported, such as small bowel adenocarcinoma, mainly located in the duodenum or jejunum. Case Presentation: We report a case of female patient celiac poor adherence to gluten-free diet who presented obstruction due primary ileal adenocarcinoma. The remains asymptomatic, adherent diet, and without clinical, biochemical, imaging evidence cancer...

10.1159/000541310 article EN cc-by-nc GE Portuguese Journal of Gastroenterology 2024-10-11

A 67-year-old female, without prior medical history, presented to the emergency department due dizziness and asthenia, where iron deficiency anemia, visible blood loss, was identified. previous abdominal computed tomography revealed intestinal pneumatosis of proximal jejunum right colon. The upper endoscopy showed non-atrophic gastritis associated with H.pylori infection, which treated, colonoscopy colic pneumatosis, other alterations. small bowel capsule performed, revealing bulging areas...

10.17235/reed.2024.10846/2024 article EN publisher-specific-oa Revista Española de Enfermedades Digestivas 2024-01-01

Introduction: Propafenone is a widely used class Ic antiarrhythmic drug that mainly metabolised by the liver. Hepatotoxicity associated with propafenone rare, only few clinical cases reported in literature. Case Presentation: We presented case of propafenone-related hepatotoxicity, cholestatic liver injury and development jaundice pruritus within 3 to 4 weeks treatment initiation. Three months after discontinuation, patient was asymptomatic, all tests normalised. Conclusion: With this case,...

10.1159/000541557 article EN cc-by-nc GE Portuguese Journal of Gastroenterology 2024-10-18

Background: Capsule panendoscopy is increasingly used in Crohn's disease (CD), particularly patients with extensive small bowel and colonic involvement. It offers a non-invasive, 1-step evaluation of both segments, making it appealing for monitoring treatment response. However, there need validated scoring systems that objectively assess inflammatory activity the colon. The aim this study was to externally validate Eliakim Score (Elk-S), developed mucosal inflammation CD by capsule...

10.14309/01.ajg.0001082684.20434.83 article EN The American Journal of Gastroenterology 2024-12-01

Background Gastric dysplasia in the absence of an endoscopically defined lesion is rare, usually either a false positive diagnosis or previously unidentified precancerous during esophagogastroduodenoscopy (EGD).

10.1080/00365521.2023.2272563 article EN Scandinavian Journal of Gastroenterology 2023-10-23

Background: Subcutaneous infliximab (SC-IFX) has been associated with a more favorable pharmacokinetic profile than intravenous (IV-IFX) in patients inflammatory bowel disease (IBD). The aim of this study was to compare serum concentrations IBD, before and after the switch from IV-IFX SC-IFX, minimum follow-up 6 months. Methods: Retrospective single-center including Crohn's (CD) ulcerative colitis (UC) clinical remission, previously medicated IV-IFX, who switched SC-IFX. In CD, remission...

10.14309/01.ajg.0000995800.05422.3b article EN The American Journal of Gastroenterology 2023-12-01
Coming Soon ...